PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

13 Mar 2018

• By Emily Hayes

ODYSSEY outcomes study homes in on value of PCSK9 inhibition for the subgroup of patients with LDL of at least 100 mg/dL, a potentially large market, but how much will payers ease restrictions in exchange for a lower price?

Arteries swelling because blood clot by fat cloged made blood flow slowly. Illustration about danger of Cholesterol.

Sanofi/Regeneron Pharmaceuticals Inc.'s release of the ODYSSEY outcomes data for Praluent (alirocumab) may be ushering in a new era for PCSK9 inhibitors, for treatment of the highest risk people at the lower cost ever, and with fewer headaches for prescribing doctors.

The ODYSSEY trial tested Praluent against placebo in 18,924 patients who had a recent acute coronary syndrome (ACS) event, most of whom (89%) were on high intensity statin treatment. Patients were followed for up to five years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.